Which has higher earnings and valuation, PCVX or ZLAB?

Zai Lab has higher revenue and earnings than Vaxcyte. Zai Lab is trading at a lower price-to-earnings ratio than Vaxcyte, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Vaxcyte N/A N/A -$766.63M -$6.88 N/A Zai Lab $453.28M 4.78 -$175.54M -$1.62 N/A

Is PCVX or ZLAB more profitable?

Vaxcyte has a net margin of 0.00% compared to Zai Lab's net margin of -39.29%. Zai Lab's return on equity of -24.32% beat Vaxcyte's return on equity. Company Net Margins Return on Equity Return on Assets Vaxcyte N/A -32.51% -29.51% Zai Lab -39.29% -24.32% -15.52%

Does the media refer more to PCVX or ZLAB?

In the previous week, Zai Lab had 5 more articles in the media than Vaxcyte. MarketBeat recorded 8 mentions for Zai Lab and 3 mentions for Vaxcyte. Vaxcyte's average media sentiment score of 0.81 beat Zai Lab's score of -0.12 indicating that Vaxcyte is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vaxcyte 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Zai Lab 2 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Which has preferable valuation and earnings, QGEN or ZLAB?

Qiagen has higher revenue and earnings than Zai Lab. Zai Lab is trading at a lower price-to-earnings ratio than Qiagen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Qiagen $2.09B 3.95 $424.88M $1.91 20.98 Zai Lab $453.28M 4.78 -$175.54M -$1.62 N/A

Is QGEN or ZLAB more profitable?

Qiagen has a net margin of 19.16% compared to Zai Lab's net margin of -39.29%. Qiagen's return on equity of 14.40% beat Zai Lab's return on equity. Company Net Margins Return on Equity Return on Assets Qiagen 19.16% 14.40% 8.40% Zai Lab -39.29% -24.32% -15.52%

Which has stronger valuation and earnings, IMVT or ZLAB?

Zai Lab has higher revenue and earnings than Immunovant. Immunovant is trading at a lower price-to-earnings ratio than Zai Lab, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Immunovant N/A N/A -$505.61M -$2.78 N/A Zai Lab $453.28M 4.78 -$175.54M -$1.62 N/A

Is IMVT or ZLAB more profitable?

Immunovant has a net margin of 0.00% compared to Zai Lab's net margin of -39.29%. Zai Lab's return on equity of -24.32% beat Immunovant's return on equity. Company Net Margins Return on Equity Return on Assets Immunovant N/A -65.66% -59.88% Zai Lab -39.29% -24.32% -15.52%

Does the media refer more to IMVT or ZLAB?

In the previous week, Zai Lab had 6 more articles in the media than Immunovant. MarketBeat recorded 8 mentions for Zai Lab and 2 mentions for Immunovant. Immunovant's average media sentiment score of 0.80 beat Zai Lab's score of -0.12 indicating that Immunovant is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immunovant 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Zai Lab 2 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media refer more to PTGX or ZLAB?

In the previous week, Zai Lab had 4 more articles in the media than Protagonist Therapeutics. MarketBeat recorded 8 mentions for Zai Lab and 4 mentions for Protagonist Therapeutics. Protagonist Therapeutics' average media sentiment score of 0.83 beat Zai Lab's score of -0.12 indicating that Protagonist Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Protagonist Therapeutics 2 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Zai Lab 2 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Which has higher earnings and valuation, ABVX or ZLAB?

Zai Lab has higher revenue and earnings than Abivax. Abivax is trading at a lower price-to-earnings ratio than Zai Lab, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Abivax N/A N/A -$380.27M -$5.21 N/A Zai Lab $453.28M 4.78 -$175.54M -$1.62 N/A

Is ABVX or ZLAB more profitable?

Abivax has a net margin of 0.00% compared to Zai Lab's net margin of -39.29%. Zai Lab's return on equity of -24.32% beat Abivax's return on equity. Company Net Margins Return on Equity Return on Assets Abivax N/A -99.02% -70.26% Zai Lab -39.29% -24.32% -15.52%

Does the media favor ABVX or ZLAB?

In the previous week, Abivax had 30 more articles in the media than Zai Lab. MarketBeat recorded 38 mentions for Abivax and 8 mentions for Zai Lab. Abivax's average media sentiment score of 0.57 beat Zai Lab's score of -0.12 indicating that Abivax is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Abivax 12 Very Positive mention(s) 3 Positive mention(s) 16 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Zai Lab 2 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Zai Lab (ZLAB) Competitors

$19.12 0.00 (0.00%)

Closing price 07/2/2026 04:00 PM Eastern

Extended Trading

$19.15 +0.03 (+0.15%)

As of 07/2/2026 07:58 PM Eastern

Compare

ZLAB vs. PCVX, QGEN, IMVT, PTGX, and ABVX

Should you buy Zai Lab stock or one of its competitors? MarketBeat compares Zai Lab with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Zai Lab include Vaxcyte (PCVX), Qiagen (QGEN), Immunovant (IMVT), Protagonist Therapeutics (PTGX), and Abivax (ABVX). These companies are all part of the "pharmaceutical products" industry.

How does Zai Lab compare to Vaxcyte?

Vaxcyte (NASDAQ:PCVX) and Zai Lab (NASDAQ:ZLAB) are both mid-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, profitability, risk, earnings, dividends and institutional ownership.

Zai Lab has higher revenue and earnings than Vaxcyte. Zai Lab is trading at a lower price-to-earnings ratio than Vaxcyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vaxcyte	N/A	N/A	-$766.63M	-$6.88	N/A
Zai Lab	$453.28M	4.78	-$175.54M	-$1.62	N/A

In the previous week, Zai Lab had 5 more articles in the media than Vaxcyte. MarketBeat recorded 8 mentions for Zai Lab and 3 mentions for Vaxcyte. Vaxcyte's average media sentiment score of 0.81 beat Zai Lab's score of -0.12 indicating that Vaxcyte is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vaxcyte	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Zai Lab	2 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Vaxcyte currently has a consensus price target of $86.00, suggesting a potential upside of 47.29%. Zai Lab has a consensus price target of $40.00, suggesting a potential upside of 109.21%. Given Zai Lab's higher possible upside, analysts clearly believe Zai Lab is more favorable than Vaxcyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vaxcyte	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Zai Lab	2 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.57

Vaxcyte has a net margin of 0.00% compared to Zai Lab's net margin of -39.29%. Zai Lab's return on equity of -24.32% beat Vaxcyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vaxcyte	N/A	-32.51%	-29.51%
Zai Lab	-39.29%	-24.32%	-15.52%

Vaxcyte has a beta of 1.22, meaning that its share price is 22% more volatile than the broader market. Comparatively, Zai Lab has a beta of 0.76, meaning that its share price is 24% less volatile than the broader market.

96.8% of Vaxcyte shares are owned by institutional investors. Comparatively, 41.7% of Zai Lab shares are owned by institutional investors. 3.3% of Vaxcyte shares are owned by company insiders. Comparatively, 4.9% of Zai Lab shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Zai Lab beats Vaxcyte on 9 of the 16 factors compared between the two stocks.

How does Zai Lab compare to Qiagen?

Qiagen (NYSE:QGEN) and Zai Lab (NASDAQ:ZLAB) are both mid-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, dividends, media sentiment, risk, profitability, earnings and institutional ownership.

In the previous week, Zai Lab had 8 more articles in the media than Qiagen. MarketBeat recorded 8 mentions for Zai Lab and 0 mentions for Qiagen. Qiagen's average media sentiment score of 0.00 beat Zai Lab's score of -0.12 indicating that Qiagen is being referred to more favorably in the media.

Company	Overall Sentiment
Qiagen	Neutral
Zai Lab	Neutral

Qiagen has higher revenue and earnings than Zai Lab. Zai Lab is trading at a lower price-to-earnings ratio than Qiagen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Qiagen	$2.09B	3.95	$424.88M	$1.91	20.98
Zai Lab	$453.28M	4.78	-$175.54M	-$1.62	N/A

Qiagen has a net margin of 19.16% compared to Zai Lab's net margin of -39.29%. Qiagen's return on equity of 14.40% beat Zai Lab's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Qiagen	19.16%	14.40%	8.40%
Zai Lab	-39.29%	-24.32%	-15.52%

Qiagen has a beta of 0.64, indicating that its stock price is 36% less volatile than the broader market. Comparatively, Zai Lab has a beta of 0.76, indicating that its stock price is 24% less volatile than the broader market.

70.0% of Qiagen shares are owned by institutional investors. Comparatively, 41.7% of Zai Lab shares are owned by institutional investors. 9.0% of Qiagen shares are owned by insiders. Comparatively, 4.9% of Zai Lab shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Qiagen presently has a consensus target price of $43.15, suggesting a potential upside of 7.65%. Zai Lab has a consensus target price of $40.00, suggesting a potential upside of 109.21%. Given Zai Lab's stronger consensus rating and higher possible upside, analysts plainly believe Zai Lab is more favorable than Qiagen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Qiagen	1 Sell rating(s)	7 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.38
Zai Lab	2 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.57

Summary

Qiagen beats Zai Lab on 10 of the 15 factors compared between the two stocks.

How does Zai Lab compare to Immunovant?

Immunovant (NASDAQ:IMVT) and Zai Lab (NASDAQ:ZLAB) are both mid-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, risk, analyst recommendations, media sentiment, earnings, valuation, profitability and institutional ownership.

Immunovant has a net margin of 0.00% compared to Zai Lab's net margin of -39.29%. Zai Lab's return on equity of -24.32% beat Immunovant's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunovant	N/A	-65.66%	-59.88%
Zai Lab	-39.29%	-24.32%	-15.52%

Immunovant has a beta of 0.76, suggesting that its share price is 24% less volatile than the broader market. Comparatively, Zai Lab has a beta of 0.76, suggesting that its share price is 24% less volatile than the broader market.

Immunovant presently has a consensus price target of $39.70, suggesting a potential upside of 2.35%. Zai Lab has a consensus price target of $40.00, suggesting a potential upside of 109.21%. Given Zai Lab's stronger consensus rating and higher probable upside, analysts clearly believe Zai Lab is more favorable than Immunovant.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunovant	1 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.45
Zai Lab	2 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.57

Zai Lab has higher revenue and earnings than Immunovant. Immunovant is trading at a lower price-to-earnings ratio than Zai Lab, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunovant	N/A	N/A	-$505.61M	-$2.78	N/A
Zai Lab	$453.28M	4.78	-$175.54M	-$1.62	N/A

In the previous week, Zai Lab had 6 more articles in the media than Immunovant. MarketBeat recorded 8 mentions for Zai Lab and 2 mentions for Immunovant. Immunovant's average media sentiment score of 0.80 beat Zai Lab's score of -0.12 indicating that Immunovant is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immunovant	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Zai Lab	2 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

47.1% of Immunovant shares are held by institutional investors. Comparatively, 41.7% of Zai Lab shares are held by institutional investors. 1.8% of Immunovant shares are held by insiders. Comparatively, 4.9% of Zai Lab shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Zai Lab beats Immunovant on 11 of the 15 factors compared between the two stocks.

How does Zai Lab compare to Protagonist Therapeutics?

Protagonist Therapeutics (NASDAQ:PTGX) and Zai Lab (NASDAQ:ZLAB) are both mid-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, earnings, dividends, media sentiment, valuation, profitability and institutional ownership.

Protagonist Therapeutics currently has a consensus target price of $115.21, suggesting a potential downside of 12.46%. Zai Lab has a consensus target price of $40.00, suggesting a potential upside of 109.21%. Given Zai Lab's higher possible upside, analysts plainly believe Zai Lab is more favorable than Protagonist Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Protagonist Therapeutics	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.88
Zai Lab	2 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.57

Zai Lab has a net margin of -39.29% compared to Protagonist Therapeutics' net margin of -154.88%. Protagonist Therapeutics' return on equity of -17.76% beat Zai Lab's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Protagonist Therapeutics	-154.88%	-17.76%	-16.47%
Zai Lab	-39.29%	-24.32%	-15.52%

Protagonist Therapeutics has higher earnings, but lower revenue than Zai Lab. Protagonist Therapeutics is trading at a lower price-to-earnings ratio than Zai Lab, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Protagonist Therapeutics	$74.06M	114.29	-$130.15M	-$1.81	N/A
Zai Lab	$453.28M	4.78	-$175.54M	-$1.62	N/A

Protagonist Therapeutics has a beta of 1.79, suggesting that its stock price is 79% more volatile than the broader market. Comparatively, Zai Lab has a beta of 0.76, suggesting that its stock price is 24% less volatile than the broader market.

98.6% of Protagonist Therapeutics shares are held by institutional investors. Comparatively, 41.7% of Zai Lab shares are held by institutional investors. 5.2% of Protagonist Therapeutics shares are held by insiders. Comparatively, 4.9% of Zai Lab shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Zai Lab had 4 more articles in the media than Protagonist Therapeutics. MarketBeat recorded 8 mentions for Zai Lab and 4 mentions for Protagonist Therapeutics. Protagonist Therapeutics' average media sentiment score of 0.83 beat Zai Lab's score of -0.12 indicating that Protagonist Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Protagonist Therapeutics	2 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Zai Lab	2 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Summary

Protagonist Therapeutics beats Zai Lab on 9 of the 16 factors compared between the two stocks.

How does Zai Lab compare to Abivax?

Abivax (NASDAQ:ABVX) and Zai Lab (NASDAQ:ZLAB) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, risk, earnings, profitability, dividends, valuation and analyst recommendations.

In the previous week, Abivax had 30 more articles in the media than Zai Lab. MarketBeat recorded 38 mentions for Abivax and 8 mentions for Zai Lab. Abivax's average media sentiment score of 0.57 beat Zai Lab's score of -0.12 indicating that Abivax is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Abivax	12 Very Positive mention(s)	3 Positive mention(s)	16 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Zai Lab	2 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Abivax has a beta of 0.87, indicating that its stock price is 13% less volatile than the broader market. Comparatively, Zai Lab has a beta of 0.76, indicating that its stock price is 24% less volatile than the broader market.

Abivax has a net margin of 0.00% compared to Zai Lab's net margin of -39.29%. Zai Lab's return on equity of -24.32% beat Abivax's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Abivax	N/A	-99.02%	-70.26%
Zai Lab	-39.29%	-24.32%	-15.52%

Abivax presently has a consensus target price of $146.00, indicating a potential upside of 0.93%. Zai Lab has a consensus target price of $40.00, indicating a potential upside of 109.21%. Given Zai Lab's higher probable upside, analysts plainly believe Zai Lab is more favorable than Abivax.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abivax	1 Sell rating(s)	1 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.81
Zai Lab	2 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.57

47.9% of Abivax shares are owned by institutional investors. Comparatively, 41.7% of Zai Lab shares are owned by institutional investors. 4.9% of Zai Lab shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Zai Lab has higher revenue and earnings than Abivax. Abivax is trading at a lower price-to-earnings ratio than Zai Lab, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abivax	N/A	N/A	-$380.27M	-$5.21	N/A
Zai Lab	$453.28M	4.78	-$175.54M	-$1.62	N/A

Summary

Zai Lab beats Abivax on 9 of the 16 factors compared between the two stocks.

Get Zai Lab News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ZLAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ZLAB vs. The Competition

Export

Metric	Zai Lab	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$2.17B	$3.78B	$7.16B	$12.48B
Dividend Yield	N/A	2.16%	2.66%	6.52%
P/E Ratio	-11.80	21.61	28.02	24.70
Price / Sales	4.78	340.22	540.55	99.42
Price / Cash	N/A	147.12	49.26	57.09
Price / Book	2.99	8.66	10.96	6.46
Net Income	-$175.54M	$23.81M	$3.57B	$337.01M
7 Day Performance	6.22%	3.39%	2.12%	1.69%
1 Month Performance	15.04%	10.81%	5.25%	3.81%
1 Year Performance	-47.52%	62.61%	33.29%	23.90%

Zai Lab Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ZLAB Zai Lab	2.1072 of 5 stars	$19.12 flat	$40.00 +109.2%	-47.5%	$2.17B	$453.28M	N/A	1,784	Insider Trade
PCVX Vaxcyte	2.2699 of 5 stars	$57.72 +2.1%	$86.00 +49.0%	+75.7%	$8.16B	N/A	N/A	160	Gap Down
QGEN Qiagen	3.3707 of 5 stars	$39.73 +0.8%	$43.15 +8.6%	-21.2%	$8.12B	$2.09B	20.75	5,654
IMVT Immunovant	1.5268 of 5 stars	$38.51 -0.9%	$37.33 -3.1%	+130.8%	$7.98B	N/A	N/A	120	Analyst Forecast
PTGX Protagonist Therapeutics	1.1022 of 5 stars	$121.63 -0.2%	$115.21 -5.3%	+157.1%	$7.84B	$46.02M	N/A	120	Analyst Forecast Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ZLAB) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Zai Lab (ZLAB) Competitors